The global sales of attenuated vaccines are projected to soar, with an estimated worth of USD 5,068.2 million in 2024 and anticipated to reach USD 9,693.9 million by 2034. This growth trajectory ...

FluMist is a live, attenuated influenza vaccine containing a weakened flu virus for the three vaccine strains. It’s approved for children as young as 2 years and adults up to age 49. “Instead of an ...

Influenza A is the most common variant of the flu and the one you’re most likely to get during pregnancy. A flu shot is the ...

AuraVax Therapeutics, Inc., a company developing novel immunotherapies to prevent and treat respiratory pathogens, today announced it has been awarded a preclinical research contract with the Division ...

The first influenza vaccine was a monovalent live-attenuated vaccine, which was used in Russia until recently. In 1940, a second strain of influenza virus was isolated; this was named influenza B ...

AuraVax collaborates with Codagenix Inc. to demonstrate NanoSTING-002 with intranasal live-attenuated vaccines ... as a candidate for a pandemic influenza vaccine. The two companies will test ...

Initial data from clinical trials evaluating H5N1/H5N2 live-attenuated influenza vaccine suggest that immunization of unprimed subjects is not associated with a serologic response that is markedly ...

Aug. 15, 2024 — A unique influenza vaccine candidate that's inhaled ... vaccine with nasal spray administration of a novel attenuated live flu virus appears to be safe and ...